There is one clinical trial.
This study is to identify the clinical criteria of drug resistant epilepsy and to explore whether SCN1A c.3184 A/G (rs2298771) and ccl2(rs1024611) polymorphisms could serve as genetic based biomarkers to predict drug resistance among epileptic patient.
Drug Resistant Epilepsy: Clinical and Genetic Study This study is to identify the clinical criteria of drug resistant epilepsy and to explore whether SCN1A c.3184 A/G (rs2298771) and ccl2(rs1024611) polymorphisms could serve as genetic based biomarkers to predict drug resistance among epileptic patient.
• Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism.
Description: • DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN). • Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism
Measure: Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism: Time: 5-7 days